The FDA completed a draft guidance that would allow drugmakers to avoid paying rebates to pharmacy benefit managers and payers, according to BioCentury.
The creation of the legal loophole is included in the FDA's guidance on drug importation. The FDA said the guidance is intended to allow drugmakers to sell imported products at lower net prices that aren't inflated due to rebate payments.
If the guidance is approved, it could enable drugmakers to create a separate but parallel market that would be for imported drugs that could be sold at lower list prices to uninsured patients or those with large deductibles.
Under the proposal, drugmakers would be allowed to receive new National Drug Codes for imported drugs. Drugmakers also would be required to make sure the imported drugs are identical to those produced for the U.S. market, according to BioCentury.
Print Page
Email to a Friend